COVID-19 drug development : : recent advances, new perspectives and applications / / Arli Aditya Parikesit, editor.
COVID-19 is a rampant worldwide problem. It is caused by the SARS-CoV-2 virus and is manifest in different variants. The Delta variant compromised existing therapeutic and preventive options for this disease and is beginning to be replaced by the Omicron variant. Through pharmaceutical biotechnology...
Saved in:
TeilnehmendeR: | |
---|---|
Place / Publishing House: | London : : IntechOpen,, 2022. |
Year of Publication: | 2022 |
Language: | English |
Physical Description: | 1 online resource (166 pages) |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
id |
993603605404498 |
---|---|
ctrlnum |
(CKB)5580000000514513 (NjHacI)995580000000514513 (EXLCZ)995580000000514513 |
collection |
bib_alma |
record_format |
marc |
spelling |
COVID-19 drug development : recent advances, new perspectives and applications / Arli Aditya Parikesit, editor. London : IntechOpen, 2022. 1 online resource (166 pages) text txt rdacontent computer c rdamedia online resource cr rdacarrier Description based on publisher supplied metadata and other sources. COVID-19 is a rampant worldwide problem. It is caused by the SARS-CoV-2 virus and is manifest in different variants. The Delta variant compromised existing therapeutic and preventive options for this disease and is beginning to be replaced by the Omicron variant. Through pharmaceutical biotechnology, three different treatment approaches to COVID-19 have been developed: computer-aided drug design (CADD); rational drug design in the wet lab; and the advanced drug delivery system. These approaches are heavily influenced by advances in life sciences, such as the development of structural bioinformatics, the establishment of nanobiotechnology as a standard approach in drug design, and major advances in structural biology such as the development of the CryoEM method. This book will focus on providing possible solutions to the ongoing COVID-19 pandemic in light of these advances in life sciences. Includes bibliographical references. 1. Introductory Chapter: Current Perspective of COVID-19 Drugs 22 -- 2. Pluralism Medical Treatment, Prevention, and Control of COVID-19 Infection and Its Long-Sufferings among the Older Adults in the Northeast of Thailand from 2019 to 2022 142 -- 3. Baricitinib in the Treatment of COVID-19 53 -- 4. New Perspective and Applications of Homeopathy in Treating COVID-19 Symptoms 28 -- 5. Treatments for the Infection by SARS-CoV-2 49 -- 6. Inclusive Review on Existing Treatment and Management Modalities for COVID-19 39 -- 7. COVID-19: From Pathophysiology to Treatment 35 -- 8. COVID-19 Drug Development: Role of Drug Repurposing 16. Drug development. 1-80356-991-3 Parikesit, Arli Aditya, editor. |
language |
English |
format |
eBook |
author2 |
Parikesit, Arli Aditya, |
author_facet |
Parikesit, Arli Aditya, |
author2_variant |
a a p aa aap |
author2_role |
TeilnehmendeR |
title |
COVID-19 drug development : recent advances, new perspectives and applications / |
spellingShingle |
COVID-19 drug development : recent advances, new perspectives and applications / 1. Introductory Chapter: Current Perspective of COVID-19 Drugs 22 -- 2. Pluralism Medical Treatment, Prevention, and Control of COVID-19 Infection and Its Long-Sufferings among the Older Adults in the Northeast of Thailand from 2019 to 2022 142 -- 3. Baricitinib in the Treatment of COVID-19 53 -- 4. New Perspective and Applications of Homeopathy in Treating COVID-19 Symptoms 28 -- 5. Treatments for the Infection by SARS-CoV-2 49 -- 6. Inclusive Review on Existing Treatment and Management Modalities for COVID-19 39 -- 7. COVID-19: From Pathophysiology to Treatment 35 -- 8. COVID-19 Drug Development: Role of Drug Repurposing 16. |
title_sub |
recent advances, new perspectives and applications / |
title_full |
COVID-19 drug development : recent advances, new perspectives and applications / Arli Aditya Parikesit, editor. |
title_fullStr |
COVID-19 drug development : recent advances, new perspectives and applications / Arli Aditya Parikesit, editor. |
title_full_unstemmed |
COVID-19 drug development : recent advances, new perspectives and applications / Arli Aditya Parikesit, editor. |
title_auth |
COVID-19 drug development : recent advances, new perspectives and applications / |
title_new |
COVID-19 drug development : |
title_sort |
covid-19 drug development : recent advances, new perspectives and applications / |
publisher |
IntechOpen, |
publishDate |
2022 |
physical |
1 online resource (166 pages) |
contents |
1. Introductory Chapter: Current Perspective of COVID-19 Drugs 22 -- 2. Pluralism Medical Treatment, Prevention, and Control of COVID-19 Infection and Its Long-Sufferings among the Older Adults in the Northeast of Thailand from 2019 to 2022 142 -- 3. Baricitinib in the Treatment of COVID-19 53 -- 4. New Perspective and Applications of Homeopathy in Treating COVID-19 Symptoms 28 -- 5. Treatments for the Infection by SARS-CoV-2 49 -- 6. Inclusive Review on Existing Treatment and Management Modalities for COVID-19 39 -- 7. COVID-19: From Pathophysiology to Treatment 35 -- 8. COVID-19 Drug Development: Role of Drug Repurposing 16. |
isbn |
1-80356-991-3 |
callnumber-first |
R - Medicine |
callnumber-subject |
RM - Therapeutics and Pharmacology |
callnumber-label |
RM301 |
callnumber-sort |
RM 3301.25 C685 42022 |
illustrated |
Not Illustrated |
dewey-hundreds |
600 - Technology |
dewey-tens |
610 - Medicine & health |
dewey-ones |
615 - Pharmacology & therapeutics |
dewey-full |
615.19 |
dewey-sort |
3615.19 |
dewey-raw |
615.19 |
dewey-search |
615.19 |
work_keys_str_mv |
AT parikesitarliaditya covid19drugdevelopmentrecentadvancesnewperspectivesandapplications |
status_str |
n |
ids_txt_mv |
(CKB)5580000000514513 (NjHacI)995580000000514513 (EXLCZ)995580000000514513 |
carrierType_str_mv |
cr |
is_hierarchy_title |
COVID-19 drug development : recent advances, new perspectives and applications / |
author2_original_writing_str_mv |
noLinkedField |
_version_ |
1796653233596268544 |
fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>02571nam a2200313 i 4500</leader><controlfield tag="001">993603605404498</controlfield><controlfield tag="005">20230625162538.0</controlfield><controlfield tag="006">m o d </controlfield><controlfield tag="007">cr |||||||||||</controlfield><controlfield tag="008">230625s2022 enk ob 000 0 eng d</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.5772/intechopen.100969</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(CKB)5580000000514513</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(NjHacI)995580000000514513</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(EXLCZ)995580000000514513</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">NjHacI</subfield><subfield code="b">eng</subfield><subfield code="e">rda</subfield><subfield code="c">NjHacl</subfield></datafield><datafield tag="050" ind1=" " ind2="4"><subfield code="a">RM301.25</subfield><subfield code="b">.C685 2022</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">615.19</subfield><subfield code="2">23</subfield></datafield><datafield tag="245" ind1="0" ind2="0"><subfield code="a">COVID-19 drug development :</subfield><subfield code="b">recent advances, new perspectives and applications /</subfield><subfield code="c">Arli Aditya Parikesit, editor.</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">London :</subfield><subfield code="b">IntechOpen,</subfield><subfield code="c">2022.</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 online resource (166 pages)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">computer</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">online resource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="588" ind1=" " ind2=" "><subfield code="a">Description based on publisher supplied metadata and other sources.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">COVID-19 is a rampant worldwide problem. It is caused by the SARS-CoV-2 virus and is manifest in different variants. The Delta variant compromised existing therapeutic and preventive options for this disease and is beginning to be replaced by the Omicron variant. Through pharmaceutical biotechnology, three different treatment approaches to COVID-19 have been developed: computer-aided drug design (CADD); rational drug design in the wet lab; and the advanced drug delivery system. These approaches are heavily influenced by advances in life sciences, such as the development of structural bioinformatics, the establishment of nanobiotechnology as a standard approach in drug design, and major advances in structural biology such as the development of the CryoEM method. This book will focus on providing possible solutions to the ongoing COVID-19 pandemic in light of these advances in life sciences.</subfield></datafield><datafield tag="504" ind1=" " ind2=" "><subfield code="a">Includes bibliographical references.</subfield></datafield><datafield tag="505" ind1="0" ind2=" "><subfield code="a">1. Introductory Chapter: Current Perspective of COVID-19 Drugs 22 -- 2. Pluralism Medical Treatment, Prevention, and Control of COVID-19 Infection and Its Long-Sufferings among the Older Adults in the Northeast of Thailand from 2019 to 2022 142 -- 3. Baricitinib in the Treatment of COVID-19 53 -- 4. New Perspective and Applications of Homeopathy in Treating COVID-19 Symptoms 28 -- 5. Treatments for the Infection by SARS-CoV-2 49 -- 6. Inclusive Review on Existing Treatment and Management Modalities for COVID-19 39 -- 7. COVID-19: From Pathophysiology to Treatment 35 -- 8. COVID-19 Drug Development: Role of Drug Repurposing 16.</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Drug development.</subfield></datafield><datafield tag="776" ind1=" " ind2=" "><subfield code="z">1-80356-991-3</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Parikesit, Arli Aditya,</subfield><subfield code="e">editor.</subfield></datafield><datafield tag="906" ind1=" " ind2=" "><subfield code="a">BOOK</subfield></datafield><datafield tag="ADM" ind1=" " ind2=" "><subfield code="b">2023-07-06 03:15:04 Europe/Vienna</subfield><subfield code="f">system</subfield><subfield code="c">marc21</subfield><subfield code="a">2023-02-11 21:29:23 Europe/Vienna</subfield><subfield code="g">false</subfield></datafield><datafield tag="AVE" ind1=" " ind2=" "><subfield code="i">DOAB Directory of Open Access Books</subfield><subfield code="P">DOAB Directory of Open Access Books</subfield><subfield code="x">https://eu02.alma.exlibrisgroup.com/view/uresolver/43ACC_OEAW/openurl?u.ignore_date_coverage=true&portfolio_pid=5343039350004498&Force_direct=true</subfield><subfield code="Z">5343039350004498</subfield><subfield code="b">Available</subfield><subfield code="8">5343039350004498</subfield></datafield></record></collection> |